266 related articles for article (PubMed ID: 25156503)
1. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Matsunaga T; Yamaji Y; Tomokuni T; Morita H; Morikawa Y; Suzuki A; Yonezawa A; Endo S; Ikari A; Iguchi K; El-Kabbani O; Tajima K; Hara A
Free Radic Res; 2014 Nov; 48(11):1371-85. PubMed ID: 25156503
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
5. Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Matsunaga T; Morikawa Y; Haga M; Endo S; Soda M; Yamamura K; El-Kabbani O; Tajima K; Ikari A; Hara A
Toxicol Appl Pharmacol; 2014 Jul; 278(2):180-9. PubMed ID: 24813866
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells.
Matsunaga T; Kawabata S; Yanagihara Y; Kezuka C; Kato M; Morikawa Y; Endo S; Chen H; Iguchi K; Ikari A
Chem Biol Interact; 2019 Dec; 314():108839. PubMed ID: 31563593
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Endo S; Xia S; Suyama M; Morikawa Y; Oguri H; Hu D; Ao Y; Takahara S; Horino Y; Hayakawa Y; Watanabe Y; Gouda H; Hara A; Kuwata K; Toyooka N; Matsunaga T; Ikari A
J Med Chem; 2017 Oct; 60(20):8441-8455. PubMed ID: 28976752
[TBL] [Abstract][Full Text] [Related]
9. Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Matsunaga T; Saito H; Endo S; Iguchi K; Soda M; El-Kabbani O; Hara A; Ikari A
Free Radic Res; 2016 Dec; 50(12):1296-1308. PubMed ID: 27629782
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
Matsunaga T; Yamane Y; Iida K; Endo S; Banno Y; El-Kabbani O; Hara A
Anticancer Drugs; 2011 Jun; 22(5):402-8. PubMed ID: 21317765
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury.
Jung M; Hotter G; Viñas JL; Sola A
Toxicol Appl Pharmacol; 2009 Jan; 234(2):236-46. PubMed ID: 19038279
[TBL] [Abstract][Full Text] [Related]
12. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
13. Development of cisplatin resistance in breast cancer MCF7 cells by up-regulating aldo-keto reductase 1C3 expression, glutathione synthesis and proteasomal proteolysis.
Kobayashi M; Yonezawa A; Takasawa H; Nagao Y; Iguchi K; Endo S; Ikari A; Matsunaga T
J Biochem; 2022 Jan; 171(1):97-108. PubMed ID: 34676395
[TBL] [Abstract][Full Text] [Related]
14. Expression of inducible nitric oxide synthase during cisplatin-based chemotherapy for gastric cancer.
Ikeguchi M; Ueta T; Kaibara N
In Vivo; 2002; 16(3):185-90. PubMed ID: 12182114
[TBL] [Abstract][Full Text] [Related]
15. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
17. CA916798 regulates multidrug resistance of lung cancer cells.
Wang HJ; Yang HP; Zhou XD; Dai XT; Chen YF; Xiong W
Asian Pac J Cancer Prev; 2011; 12(12):3403-8. PubMed ID: 22471488
[TBL] [Abstract][Full Text] [Related]
18. The role of caspase family protease, caspase-3 on cisplatin-induced apoptosis in cisplatin-resistant A431 cell line.
Mese H; Sasaki A; Nakayama S; Alcalde RE; Matsumura T
Cancer Chemother Pharmacol; 2000; 46(3):241-5. PubMed ID: 11021742
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination.
Chanvorachote P; Nimmannit U; Stehlik C; Wang L; Jiang BH; Ongpipatanakul B; Rojanasakul Y
Cancer Res; 2006 Jun; 66(12):6353-60. PubMed ID: 16778213
[TBL] [Abstract][Full Text] [Related]
20. Accumulation and photodynamic activity of chlorin e6 in cisplatin-resistant human lung cancer cells.
Horibe S; Nagai J; Yumoto R; Tawa R; Takano M
J Pharm Sci; 2011 Jul; 100(7):3010-7. PubMed ID: 21274848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
